<DOC>
	<DOCNO>NCT01105650</DOCNO>
	<brief_summary>This single center phase II trial design optimize clinical platform lymphodepleting chemotherapy T-cell suppression promote persistence , function , expansion allogeneic natural killer ( NK ) cell patient recurrent ovarian , fallopian tube , primary peritoneal cancer advance metastatic breast cancer .</brief_summary>
	<brief_title>Allogeneic Natural Killer ( NK ) Cells Ovarian , Fallopian Tube , Peritoneal Metastatic Breast Cancer</brief_title>
	<detailed_description>The donor NK cell infuse day 0 , non-myeloablative preparative regimen cyclophosphamide fludarabine plus cyclosporine A ( CsA ) base immunosuppressive therapy . Subcutaneous interleukin-2 ( IL-2 ) start even NK infusion continue three time week 6 dos total . Up 4 sequential immunosuppressive platform test ( Arms 1 2 currently close ) identify platform patient potential successful NK cell expansion ( define absolute circulate donor derive NK cell count &gt; 100 cells/Î¼l 14 day NK cell infusion ) . Once clinical platform determine , platform expand total 18 patient . The primary goal extend phase obtain preliminary efficacy information . Follow-up disease response 1 year NK cell infusion , possibility re-treatment patient experience least clinical benefit progress 6 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Diagnosis recurrent ovarian cancer , fallopian tube , primary peritoneal cancer fail progress least 2 prior salvage chemotherapy regimen ( direct recurrent/metastatic disease ) . OR Diagnosis metastatic breast cancer ( female male ) progress fail least one salvage chemotherapy regimen metastatic disease meet follow disease specific related criterion : If estrogen receptor progesterone receptor positive must progress prior hormonal therapy and/or HER2neu positive must progress trastuzumab , lapatinib , similar agent Women history cancer eligible study provide currently meet eligibility one diseases . Women another malignancy disease free least 3 year , history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible . Measurable disease per disease specific Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 patient bone site disease eligible . If history brain metastasis must stable least 3 month treatment A brain compute tomography ( CT ) scan require subject know brain metastasis time enrollment subject clinical sign symptom suggestive brain metastasis . Available related HLAhaploidentical natural killer ( NK ) cell donor ( least class I serologic type A &amp; B locus ) Age 18 year old Karnofsky performance status &gt; = 50 % Adequate organ function determine follow criterion within 14 day study enrollment Bone marrow : platelet &gt; = 80,000 x 10^9/L hemoglobin &gt; = 9 g/dL , unsupported transfusion ; absolute neutrophil count ( ANC ) &gt; = 1000 x 10^9/L , unsupported growth colony stimulate factor ( GCSF ) granulocytemacrophage colonystimulating factor ( GMCSF ) Renal function : creatinine ( Cr ) &lt; = 2.0 mg/dL Liver function : Aspartate aminotransferase ( AST ) , Alanine transaminase ( ALT ) , total bilirubin , alkaline phosphatase &lt; 5 time upper limit institutional normal ( ULN ) Cardiac : Left ventricular ejection fraction &gt; 40 % ( within 28 day treatment start ) Pulmonary function : &gt; 50 % correct Carbon Monoxide Diffusing Capacity ( DLCO ) Forced Expiratory Volume One Second ( FEV1 ) , presence pleural effusion due metastatic disease &gt; 40 % correct DLCO FEV1 acceptable ( within 28 day treatment start ) Able prednisone immunosuppressive medication least 3 day prior Day 0 At least 14 day must lapse last prior anticancer treatment 1st day preparative regimen Voluntary write informed consent Pregnant nurse The agent use study may teratogenic fetus information excretion agent breast milk . Participants childbearing potential must blood test urine study within 14 day prior registration rule pregnancy agree use adequate birth control study treatment Active infection subject must afebrile , antibiotic , uninvestigated radiologic lesion ( infiltrates lesion negative culture biopsy ) allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>recurrent ovarian cancer</keyword>
	<keyword>recurrent fallopian tube cancer</keyword>
	<keyword>recurrent primary peritoneal cancer</keyword>
	<keyword>refractory ovarian cancer</keyword>
	<keyword>refractory fallopian tube cancer</keyword>
	<keyword>refractory peritoneal cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
</DOC>